Amgen: Multiple Myeloma trials

The registry lists 42 Multiple Myeloma studies with Amgen as lead sponsor. 0 are open to participants now and 35 have results posted.

Phase 1 18Phase 2 16Phase 3 11Phase 4 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib TripletCompletedNCT04191616Phase 2Results posted
• Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple MyelomaCompletedNCT03934684Phase 4Results posted
• A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03859427Phase 3Results posted
• A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology CentersTerminatedNCT03512353Phase 2Results posted
• Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesTerminatedNCT03465540Phase 1Results posted
• Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.CompletedNCT03158688Phase 3Results posted
• Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Phase 3Results posted
• Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple MyelomaCompletedNCT02939183Phase 1Results posted
• AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02675452Phase 1Results posted
• A Phase 1 Study in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT02561962Phase 1Results posted
• Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple MyelomaCompletedNCT02412878Phase 3Results posted
• Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02335983Phase 1Results posted
• A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple MyelomaTerminatedNCT01999335Phase 1Results posted
• A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma SubjectsCompletedNCT01980589Phase 1Results posted
• Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal DiseaseCompletedNCT01949532Phase 1Results posted
• Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple MyelomaTerminatedNCT01881789Phase 1/2Results posted
• Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT01832727Phase 1/2Results posted
• Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple MyelomaCompletedNCT01818752Phase 3Results posted
• A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple MyelomaCompletedNCT01677858Phase 1/2Results posted
• Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma PatientsCompletedNCT01568866Phase 3Results posted
• Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple MyelomaCompletedNCT01345019Phase 3Results posted
• A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01302392Phase 3Results posted
• Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple MyelomaCompletedNCT01080391Phase 3Results posted
• Open Label Extension to SRE Studies in United Kingdom and Czech Republic OnlyCompletedNCT00950911Phase 3Results posted
• Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumCompletedNCT00896454Phase 2Results posted
• A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment ProtocolsCompletedNCT00884312Phase 2Results posted
• Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal FunctionCompletedNCT00721734Phase 2Results posted
• Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple MyelomaCompletedNCT00603447Phase 1Results posted
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaCompletedNCT00531284Phase 1/2Results posted
• Phase 2 Study of Carfilzomib in Relapsed Multiple MyelomaCompletedNCT00530816Phase 2Results posted
• Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple MyelomaCompletedNCT00511238Phase 2Results posted
• Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.CompletedNCT00330759Phase 3Results posted
• Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - DenosumabCompletedNCT00259740Phase 2Results posted
• Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological MalignanciesCompletedNCT00150462Phase 1Results posted
• Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) BisphosphonatesCompletedNCT00104650Phase 2Results posted
• A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnNCT04998747Phase 1
• A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT03287908Phase 1
• Real-world Use of Carfilzomib Among Multiple Myeloma Patients in EuropeCompletedNCT03091127
• A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02072863Phase 1/2
• Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic MalignanciesTerminatedNCT01416428Phase 1/2
• Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory DiseaseApproved for marketingNCT01410500
• Chemotherapy Related Anemia in Patients With Non-Myeloid MalignanciesCompletedNCT00036023Phase 2